In this study, we focused on investigating the mechanism by which Id4 restores the biological activity of mutant p53, clearly an area of high interest given that mutant p53 is observed in one third of prostate cancer[27,28] and more than 50% of all cancers[48]. Here, TP53 is linked to prostate carcinoma.